ITMI20021392A1 - Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' - Google Patents

Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Info

Publication number
ITMI20021392A1
ITMI20021392A1 IT2002MI001392A ITMI20021392A ITMI20021392A1 IT MI20021392 A1 ITMI20021392 A1 IT MI20021392A1 IT 2002MI001392 A IT2002MI001392 A IT 2002MI001392A IT MI20021392 A ITMI20021392 A IT MI20021392A IT MI20021392 A1 ITMI20021392 A1 IT MI20021392A1
Authority
IT
Italy
Prior art keywords
liquid drugs
ambient temperature
oral administration
pharmaceutical forms
better bioavailability
Prior art date
Application number
IT2002MI001392A
Other languages
English (en)
Italian (it)
Inventor
Giancarlo Santus
Soldato Piero Del
Cristina Macelloni
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Priority to IT2002MI001392A priority Critical patent/ITMI20021392A1/it
Publication of ITMI20021392A0 publication Critical patent/ITMI20021392A0/it
Priority to DE60312523T priority patent/DE60312523T2/de
Priority to IL16560103A priority patent/IL165601A0/xx
Priority to HK06100214.4A priority patent/HK1080364B/zh
Priority to NZ537204A priority patent/NZ537204A/en
Priority to CA002491152A priority patent/CA2491152A1/en
Priority to CNB038151812A priority patent/CN1319518C/zh
Priority to PCT/EP2003/006496 priority patent/WO2004000273A1/en
Priority to KR1020047021307A priority patent/KR20060076136A/ko
Priority to AU2003246564A priority patent/AU2003246564B2/en
Priority to PT03760660T priority patent/PT1526839E/pt
Priority to US10/515,621 priority patent/US20060171969A1/en
Priority to ES03760660T priority patent/ES2285182T3/es
Priority to EP03760660A priority patent/EP1526839B1/en
Priority to DK03760660T priority patent/DK1526839T3/da
Priority to AT03760660T priority patent/ATE356612T1/de
Priority to SI200330822T priority patent/SI1526839T1/sl
Priority to PL374388A priority patent/PL206599B1/pl
Priority to RU2004138554/15A priority patent/RU2323003C2/ru
Priority to MXPA04012852A priority patent/MXPA04012852A/es
Priority to JP2004514802A priority patent/JP2005530835A/ja
Publication of ITMI20021392A1 publication Critical patent/ITMI20021392A1/it
Priority to ZA200410109A priority patent/ZA200410109B/xx
Priority to NO20050347A priority patent/NO20050347L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2002MI001392A 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' ITMI20021392A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
JP2004514802A JP2005530835A (ja) 2002-06-25 2003-06-20 改良された生物学的利用能を有する液体薬剤の経口医薬形態
PT03760660T PT1526839E (pt) 2002-06-25 2003-06-20 Formas farmacêuticas orais de fármacos líquidos com biodisponibilidade melhorada
ES03760660T ES2285182T3 (es) 2002-06-25 2003-06-20 Farmacos liquidos en formas orales solidas que tienen biodisponibilidad mejorada.
HK06100214.4A HK1080364B (zh) 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型
NZ537204A NZ537204A (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
CA002491152A CA2491152A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
CNB038151812A CN1319518C (zh) 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型
PCT/EP2003/006496 WO2004000273A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
KR1020047021307A KR20060076136A (ko) 2002-06-25 2003-06-20 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들
AU2003246564A AU2003246564B2 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
DE60312523T DE60312523T2 (de) 2002-06-25 2003-06-20 Orale, pharmazeutische Darreichungsformen von flüssigen Medikamenten mit verbesserter Bioverfügbarkeit
US10/515,621 US20060171969A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
IL16560103A IL165601A0 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
EP03760660A EP1526839B1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
DK03760660T DK1526839T3 (da) 2002-06-25 2003-06-20 Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
AT03760660T ATE356612T1 (de) 2002-06-25 2003-06-20 Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
SI200330822T SI1526839T1 (sl) 2002-06-25 2003-06-20 Oralne farmacevtske oblike tekočih zdravil z izboljšano biološko uporabnostjo
PL374388A PL206599B1 (pl) 2002-06-25 2003-06-20 Kompozycje farmaceutyczne do podawania doustnego ciekłych leków
RU2004138554/15A RU2323003C2 (ru) 2002-06-25 2003-06-20 Пероральные фармацевтические формы жидких лекарственных средств, имеющих улучшенную биодоступность
MXPA04012852A MXPA04012852A (es) 2002-06-25 2003-06-20 Formas farmaceutica orales de farmacos liquidos que tienen biodisponibilidad mejorada.
ZA200410109A ZA200410109B (en) 2002-06-25 2004-12-14 Oral pharmaceutical forms of liquid drugs having improved bioavailability.
NO20050347A NO20050347L (no) 2002-06-25 2005-01-21 Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Publications (2)

Publication Number Publication Date
ITMI20021392A0 ITMI20021392A0 (it) 2002-06-25
ITMI20021392A1 true ITMI20021392A1 (it) 2003-12-29

Family

ID=11450079

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Country Status (23)

Country Link
US (1) US20060171969A1 (https=)
EP (1) EP1526839B1 (https=)
JP (1) JP2005530835A (https=)
KR (1) KR20060076136A (https=)
CN (1) CN1319518C (https=)
AT (1) ATE356612T1 (https=)
AU (1) AU2003246564B2 (https=)
CA (1) CA2491152A1 (https=)
DE (1) DE60312523T2 (https=)
DK (1) DK1526839T3 (https=)
ES (1) ES2285182T3 (https=)
HK (1) HK1080364B (https=)
IL (1) IL165601A0 (https=)
IT (1) ITMI20021392A1 (https=)
MX (1) MXPA04012852A (https=)
NO (1) NO20050347L (https=)
NZ (1) NZ537204A (https=)
PL (1) PL206599B1 (https=)
PT (1) PT1526839E (https=)
RU (1) RU2323003C2 (https=)
SI (1) SI1526839T1 (https=)
WO (1) WO2004000273A1 (https=)
ZA (1) ZA200410109B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030148818A1 (en) * 2002-01-18 2003-08-07 Myrhum Mark C. Golf club woods with wood club head having a selectable center of gravity and a selectable shaft
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
PL1879466T5 (pl) * 2005-03-04 2016-07-29 Dsm Ip Assets Bv Spożywcza cząsteczkowa kompozycja lipidowa
US20080260816A1 (en) * 2005-09-16 2008-10-23 Bengt Herslof Particulate Lipid Pharmaceutical Composition
US20080293781A1 (en) 2005-11-23 2008-11-27 Alberto Gasco Salicylic Acid Derivatives
EP2786749A1 (en) * 2006-02-03 2014-10-08 Nicox S.A. Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
MX2009011493A (es) * 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
WO2009149053A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
CN105188677A (zh) 2013-03-13 2015-12-23 特瑞斯制药股份有限公司 苯佐那酯调释固体片剂和胶囊剂
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
MX2022007085A (es) * 2019-12-09 2022-08-19 Nicoventures Trading Ltd Nanoemulsion para uso oral.
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.
IL312564A (en) 2021-11-05 2024-07-01 Cinclus Pharma Holding Ab Publ Polymorphs of the hydrochloride salt of linfarezan glurate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5266615A (en) * 1975-11-29 1977-06-02 Sawai Seiyaku Kk Manufacturing of solidified oily liquid substance
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
JPS58213073A (ja) * 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
EP1140027B1 (en) * 1998-12-23 2005-10-12 Alza Corporation Dosage forms comprising porous particles
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition

Also Published As

Publication number Publication date
WO2004000273A1 (en) 2003-12-31
HK1080364A1 (en) 2006-04-28
ATE356612T1 (de) 2007-04-15
MXPA04012852A (es) 2005-06-08
RU2323003C2 (ru) 2008-04-27
EP1526839B1 (en) 2007-03-14
JP2005530835A (ja) 2005-10-13
KR20060076136A (ko) 2006-07-04
PL206599B1 (pl) 2010-08-31
SI1526839T1 (sl) 2007-08-31
NZ537204A (en) 2006-07-28
EP1526839A1 (en) 2005-05-04
PL374388A1 (en) 2005-10-17
CN1665486A (zh) 2005-09-07
HK1080364B (zh) 2008-02-01
US20060171969A1 (en) 2006-08-03
NO20050347L (no) 2005-01-21
ITMI20021392A0 (it) 2002-06-25
AU2003246564B2 (en) 2008-06-12
IL165601A0 (en) 2006-01-15
CN1319518C (zh) 2007-06-06
PT1526839E (pt) 2007-06-06
RU2004138554A (ru) 2005-08-27
ES2285182T3 (es) 2007-11-16
CA2491152A1 (en) 2003-12-31
DE60312523D1 (de) 2007-04-26
AU2003246564A1 (en) 2004-01-06
DE60312523T2 (de) 2008-01-10
ZA200410109B (en) 2005-09-02
DK1526839T3 (da) 2007-05-21

Similar Documents

Publication Publication Date Title
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
WO2003105800A3 (de) Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
TR200002812T2 (tr) Efervesan formülasyonları.
EP1708686A4 (en) GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
NO20016107L (no) Mesalazin-kontrollert frigivelse orale farmasöytiske sammensetninger
FR2825023B1 (fr) Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
EA200400432A1 (ru) Производные мочевины
DE69808463D1 (de) Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ITMI20021726A1 (it) Macrolidi ad attivita' antiinfiammatoria.
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
BR0302523A (pt) Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
FR2843301B1 (fr) Forme galenique pour la delivrance colique de principes actifs
FR2839645B1 (fr) Systeme multilamellaire pour l'administration de substances actives (en particulier des medicaments) par ingestion par la voie orale